TNB forms joint venture with Luminous Aspect, SME consortium for 500MW solar project
Bitget2026/11/03 09:19- Tenaga Nasional's subsidiary TNB Renewables signed a solar joint venture agreement with Luminous Aspect and CSP 500MW on November 3, 2026.
- The project in Bahau, Negeri Sembilan, comprises 500MWac of solar capacity with a 250MW/1,000MWh battery energy storage system.
- TNB Renewables holds 70% of the venture; IOI subsidiary Luminous Aspect owns 25%, with SME consortium CSP 500MW holding 5%.
- The parent will inject up to RM 424.4 million through Ordinary Shares and Redeemable Preference Shares into TNB Renewables for the project.
- Maximum equity capitalization is RM 606.2 million, with a planned debt-to-equity ratio of up to 80:20, subject to funding conditions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.